Browsing Tag
AbbVie
63 posts
Lundbeck’s Vyepti shows real-world migraine relief in patients failed by prior CGRP treatments
New INFUSE study data shows Vyepti may improve outcomes in migraine patients unresponsive to CGRP therapies. Find out what this means for the market.
Emmecell names ex-AbbVie executive Ramin Valian as CEO to lead cell therapy platform
Emmecell names Ramin Valian as CEO to guide its magnetic cell delivery platform toward pivotal trials. Find out what this leadership shift means for the industry.
Emmecell taps AbbVie veteran Ramin Valian as CEO to lead magnetic cell therapy into pivotal trials
Emmecell has named former AbbVie executive Ramin Valian as CEO to lead its magnetic cell therapy platform into pivotal trials. Find out what this signals next.
AbbVie strengthens U.S. manufacturing strategy with Arizona facility deal, reinforcing long-term supply resilience
Find out how AbbVie’s Arizona manufacturing acquisition strengthens U.S. drug production and reinforces long-term supply resilience.
FDA authorizes breakthrough Epkinly regimen from AbbVie for relapsed or refractory follicular lymphoma
Discover how AbbVie’s newly approved Epkinly regimen with rituximab and lenalidomide is redefining treatment for relapsed or refractory follicular lymphoma.
Breakthrough REZOLVE-AD results position Rezpegaldesleukin as a potential first-in-class IL-2 Treg therapy for atopic dermatitis and asthma
Rezpegaldesleukin delivers strong dual skin and asthma results in the REZOLVE-AD study — find out how Nektar Therapeutics plans to advance its IL-2 Treg platform in 2026.
Are short-acting psychedelics the next big bet in mental health? What pharma’s billion-dollar moves suggest
Are short-acting psychedelics the future of psychiatry? Pharma’s billion-dollar bets say yes. We explore what’s behind the new wave of scalable mental health drugs.
AbbVie completes $1.2bn acquisition of Gilgamesh’s bretisilocin: Is big pharma finally embracing psychedelic psychiatry?
AbbVie completes $1.2B acquisition of bretisilocin from Gilgamesh, betting big on short-acting psychiatric drugs. Here’s what the deal signals for depression care.
AbbVie wins FDA nod expanding RINVOQ label to Crohn’s disease in major IBD market milestone
Find out how AbbVie’s FDA approval for RINVOQ in Crohn’s disease is reshaping IBD therapy and boosting investor confidence in its post-Humira strategy.
Can AbbVie’s RINVOQ fill the biologics gap for IBD patients unsuitable for TNF therapy?
AbbVie gets FDA approval for broader RINVOQ use in IBD patients beyond TNF blockers. Find out how this impacts stock sentiment and investor expectations.